Pilot Clinical Evaluation to Characterize in Vivo Effects of Topically Applied ZuraPrep & ZuraPrep Vehicle

Surgical Site Infection Clinical Trial

Official title:

Pilot Clinical Evaluation to Characterize the in Vivo Effects of Topically Applied ZuraPrep and ZuraPrep Vehicle

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02578771
• Other study ID #: ZX-ZP-0068 (MBT#865-104)
• Status: Completed
• Phase: Phase 3
• First received: October 8, 2015
• Last updated: July 13, 2017
• Start date: October 2015
• Est. completion date: January 2016

Study information

• Verified date: July 2017
• Source: Zurex Pharma, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

ZuraPrep is being evaluated for efficacy as a preoperative skin preparation solution to demonstrate its immediate and persistent antimicrobial properties. At least 72 subjects will be randomized utilizing bilateral applications on abdomen and groin. ZuraPrep active product and reference positive control will be compared; ZuraPrep non-active and negative control will be compared. Each subject will receive two of the planned treatments, one on the left side of body and one of the right. Study duration for subjects - 3 to 4 weeks.

Description:

The single investigational test article, ZuraPrep solution is being evaluated for efficacy as a preoperative skin preparation solution to demonstrate its immediate and persistent antimicrobial properties. At least 72 subjects will be randomized utilizing bilateral applications on abdomen and groin.

The primary objective of this study is to characterize the in vivo effects of the ZuraPrep test article compared to the positive reference control ChloraPrep, as well as to evaluate the ZuraPrep test vehicle to the negative control, Saline, using the newly proposed sampling intervals.

This is a randomized, paired-comparisons design where each subject will receive two of the planned treatments, one on the left side of body and one on the right. Treatments will be evaluated at 30 seconds, 10 minutes and 6 hour sampling intervals compared to baseline. Status will be calculated separately for the abdomen and groin for each side of the body.

Study duration for subjects - 3 to 4 weeks.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 123
• Est. completion date: January 2016
• Est. primary completion date: January 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Healthy male and female volunteers, 18 years of age or older.

• Are in good general health.

• Have skin within 6 inches of the test sites that is free of tattoos, dermatoses, abrasions, cuts, lesions or other skin disorders.

• Cooperative and willing to follow Subject Instructions.

• Cooperative and willing to sign Consent Form and HIPAA Authorization Form.

• Have acceptable Screening Day baseline counts (CFU/cm2).

Exclusion Criteria:

• Topical or systemic antimicrobial exposure within 14 days prior to Screening Day. Restrictions include, but are not limited to antimicrobial soaps, antiperspirants/deodorants, shampoos, lotions, perfumes, after shaves, colognes, and topical or systemic antibiotics.

• Swimming in chemically treated pools or bathing in hot tubs, spas and whirlpools within 14 days prior to Screening Day.

• Use of tanning beds, hot waxes, or depilatories, including shaving (in the applicable test areas) within 14 days prior to Screening Day.

• Contact with solvents, acids, bases, fabric softener-treated clothing or other household chemicals in the applicable test areas within 14 days prior to Screening Day.

• Subjects who have a history of sensitivity to natural rubber latex, adhesive skin products (e.g., Band-Aids, medical tapes), isopropyl alcohol, citric acid, methylene blue, methylparaben, propylparaben, or chlorhexidine gluconate products.

• Subjects who have a history of skin allergies.

• Subjects who have a history of skin cancer within 6 inches of the applicable test areas.

• Subjects who are pregnant, attempting pregnancy or nursing. For all females of child-bearing potential (<60 years of age), a urine pregnancy test will be performed prior to treatment on Treatment Day.

• Subjects who have showered or bathed within 72 hours of the Screening Day or Treatment Day (sponge baths may be taken, however, the lower abdomen and upper thigh region must be avoided).

• Subjects who receive an irritation score of 1 for any individual skin condition prior to Screening Day baseline or Treatment Day baseline sample collection.

• Participation in another clinical trial in the 30 days prior to Test Day of this study (treatment with test materials in this study), or be currently enrolled in another clinical trial, or has previously participated in this study.

Related Conditions & MeSH terms

• Surgical Site Infection
• Surgical Wound Infection

Intervention

Drug:
• ZuraPrep with 70% IPA
Apply topically
• ZuraPrep without 70% IPA
Apply topically. 0% IPA
• ChloraPrep CHG/IPA Teal Tint
Apply topically

Other:
• Normal Saline
Apply topically

Locations

Country	Name	City	State
United States	MicroBioTest	Sterling	Virginia

Sponsors (1)

Lead Sponsor	Collaborator
Zurex Pharma, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Reduction of skin flora measured by Tentative Final Monograph (TFM) Proposed Amendment	calculated as log-10 CFU responder rates from baseline	30 seconds
Primary	Reduction of skin flora measured by 1994 TFM	calculated as log-10 CFU reductions from baseline	10 minutes
Secondary	Skin flora measurement	The bacterial counts should not exceed baseline at the 6 hour sampling time	6 hours